Search Results for: "Clinic Roundup"
-
Clinic Roundup
The randomized, placebo-controlled trial achieved statistical significance for its primary endpoint of mean number of oral ulcers at week 12BioWorld Today | Monday, June 17, 2013 -
Clinic Roundup
The primary endpoint is tumor regression...Overall survival is the primary endpoint. (See BioWorld Today, Dec. 22, 2010BioWorld Today | Friday, June 14, 2013 -
Pharma: Clinic Roundup
Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase III study published in The Lancet showed patients with active psoriatic arthritis who received either Stelara (ustekinumab) 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint, compared to patients receiving placeboBioWorld Today | Friday, June 14, 2013 -
Clinic Roundup
It will enroll 636 subjects, randomized equally to all three treatment arms, with a primary endpoint of time to alleviation of influenzaBioWorld Today | Thursday, June 13, 2013 -
Clinic Roundup
The primary endpoints are immunogenicity evaluated 21 days after each administration, as well as safety and tolerability after each administration and 12 months after the last injectionBioWorld Today | Wednesday, June 12, 2013 -
Pharma: Clinic Roundup
The primary endpoint was viral cure 12 weeks after completion of treatmentBioWorld Today | Tuesday, June 11, 2013 -
Clinic Roundup
The primary endpoint of the Phase II cohort is to assess the complete remission rate...The primary endpoint of the study is to demonstrate efficacy, tolerability and safety of TI-001, with the secondary goal of determining the best Phase III dosage and exploring interlukin-6 levels as a potential biomarker for predicting efficacyBioWorld Today | Tuesday, June 11, 2013 -
Clinic Roundup
The study met its primary endpoint of lowering LDL-C, which it did by an average of 32 percent...The primary endpoints of the trial will be progression-free survival and overall survivalBioWorld Today | Monday, June 10, 2013 -
Clinic Roundup
In the SET study, tasimelteon achieved the primary endpoints of entrainment (synchronizing) of the melatonin (aMT6s) rhythm as compared to placebo and clinical response as measured by entrainment plus a score of greater than or equal to 3 on the Non-24 Clinical Response ScaleBioWorld Today | Friday, June 7, 2013 -
Clinic Roundup
The primary endpoint is the number of combined unique active lesions after 24 weeks of treatment, compared to baselineBioWorld Today | Thursday, June 6, 2013 -
Clinic Roundup
The Phase III randomized, placebo-controlled study will assess efficacy and safety of the drug with a primary endpoint as change in truncal fat mass from baseline to six months after beginning treatmentBioWorld Today | Wednesday, June 5, 2013 -
Clinic Roundup
The primary endpoint of this trial is progression free survivalBioWorld Today | Tuesday, June 4, 2013 -
Clinic Roundup
ALKS 5461 met its primary endpoint, met key secondary endpoints and demonstrated significant reduction in depressive symptoms versus placebo...The primary endpoint for the trial is progression-free survival. (See BioWorld Today, Aug. 7, 2012BioWorld Today | Monday, June 3, 2013 -
Clinic Roundup
Amitifadine efficacy at 50-mg or 100-mg doses did not show a statistically significant difference from placebo in the primary endpoint of a change in MADRS (Montgomery-Åsberg Depression Rating Scale...The Phase IIb study is a double-blind, placebo-controlled, randomized, parallel group trial planned to be conducted at sites in the U.S. The study's co-primary endpoints are change in micturition frequency per 24 hours and change in urinary incontinence episodes per 24 hours, in each case fromBioWorld Today | Thursday, May 30, 2013 -
Pharma: Clinic Roundup
Results from the study's primary endpoint showed that at 18 months, both Forteo and risedronate significantly increased lumbar spine vBMD, and greater increases were observed in patients taking Forteo (mean change from baseline: 16.3% vs. 3.8%; p = 0.004...chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL) met its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRCBioWorld Today | Thursday, May 30, 2013 -
Clinic Roundup
In a meeting between the agency and the company, it was agreed that the primary indication and label for Proellex-V should be for treatment of severe menstrual bleeding associated with fibroids, using the Pictorial Blood Loss Assessment as primary endpoint, and that if the company proposes a label based on patient-reported outcome, that must be validated prior to the start of Phase III...While the primary endpoint is safety, secondary objectives include an analysis of dose vsBioWorld Today | Friday, May 24, 2013 -
Clinic Roundup
The exploratory analysis identified a more robust response to CERE-120 in Parkinson's patients diagnosed within five years prior to treatment relative to those diagnosed 10 years or older (p < 0.005), as measured by change from baseline on the Unified Parkinson's Disease Rating Scale, the primary endpoint...Previously, Ceregene reported the primary endpoint was not met for the overall study population, although a key secondary endpoint of diary-hours off demonstrated statistical significance and noBioWorld Today | Thursday, May 23, 2013 -
Clinic Roundup
Results of the trial's primary endpoint of change in fasting plasma glucose are expected in late summer, and the read-out for long-term glucose lowering and weight benefits is due in the fourth quarter...Overall survival will be the primary endpointBioWorld Today | Tuesday, May 21, 2013 -
Clinic Roundup
Patients treated with afatinib lived for almost a year before their tumor started to grow again (progression-free survival [PFS], the primary endpoint) as compared with just under six months for patients treated with gemcitabine/cisplatin...In the study, at Day 28 (primary endpoint, p = 0.26), 24 percent of treated patients achieved resolution compared to 12 percent in the sham injection armBioWorld Today | Friday, May 17, 2013 -
Clinic Roundup
The primary endpoint in Phase II will be progression-free survivalBioWorld Today | Thursday, May 16, 2013
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.